The impact of DC10 treatment on serum allergen-specific IgE/IgG1 levels lags somewhat behind their effects on the airway Th2 recall responses to allergen challenge or on airway hyperresponsiveness (AHR), but nevertheless the levels of IgE and IgG1 in DC10-treated mice approach background within ≈4 months of a single treatment [16]. Here, IGHE is linked to airway hyperresponsiveness.